Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gore

Showing results (11-20 of 138) with videos related to

Pageof 14
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 26, 2013
Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trialMark Fisher, Martin Gore
Gynecologic Oncology|February 15, 2003
Specific keynote: clinical trial design problems in ovarian cancerAnna Stevenson, Martin Gore
Therapeutic Advances in Medical Oncology|July 27, 2011
Which patients with renal cancer may benefit from sunitinib therapy?Tom Ferguson, Martin Gore
Drugs in R&D|June 18, 2011
Axitinib for the management of metastatic renal cell carcinomaBernard Escudier, Martin Gore
The Lancet. Oncology|December 19, 2015
Precision oncology: where next?Martin Gore, James Larkin
The Oncologist|July 14, 2009
The future of targeted therapies in ovarian cancerSusana Banerjee, Martin Gore
Critical Reviews in Oncology/Hematology|June 15, 2007
Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapyNicoletta Colombo, Martin Gore
The Lancet. Oncology|September 10, 2002
Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent diseaseMark Harries, Martin Gore
Current Oncology Reports|March 28, 2013
Personalized therapy in gynecological cancer: a reality in clinical practice?Susana Banerjee, Martin Gore
Expert Opinion on Pharmacotherapy|October 27, 2004
Review of the use of topotecan in ovarian carcinomaTanya Ahmad, Martin Gore
Pageof 14

Showing results (11-20 of 138) with videos related to

Sort By:
Pageof 14
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 26, 2013
Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trialMark Fisher, Martin Gore
Gynecologic Oncology|February 15, 2003
Specific keynote: clinical trial design problems in ovarian cancerAnna Stevenson, Martin Gore
Therapeutic Advances in Medical Oncology|July 27, 2011
Which patients with renal cancer may benefit from sunitinib therapy?Tom Ferguson, Martin Gore
Drugs in R&D|June 18, 2011
Axitinib for the management of metastatic renal cell carcinomaBernard Escudier, Martin Gore
The Lancet. Oncology|December 19, 2015
Precision oncology: where next?Martin Gore, James Larkin
The Oncologist|July 14, 2009
The future of targeted therapies in ovarian cancerSusana Banerjee, Martin Gore
Critical Reviews in Oncology/Hematology|June 15, 2007
Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapyNicoletta Colombo, Martin Gore
The Lancet. Oncology|September 10, 2002
Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent diseaseMark Harries, Martin Gore
Current Oncology Reports|March 28, 2013
Personalized therapy in gynecological cancer: a reality in clinical practice?Susana Banerjee, Martin Gore
Expert Opinion on Pharmacotherapy|October 27, 2004
Review of the use of topotecan in ovarian carcinomaTanya Ahmad, Martin Gore
Pageof 14